Finch Therapeutics Group (FNCH)
(Delayed Data from OTC)
$11.50 USD
+0.24 (2.13%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Finch Therapeutics Group, Inc. [FNCH]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Company: Finch Therapeutics Group, Inc.
Industry: Medical - Drugs
Company: Finch Therapeutics Group, Inc.
Industry: Medical - Drugs
Expenses Continued to Wind Down in 2Q23; Reiterate Buy Rating With a Post-Reverse Stock Split Adjusted PT of $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Finch Therapeutics Group, Inc.
Industry: Medical - Drugs
The Sighting of a New Finch Brings Promise; Reiterate Buy Rating and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Finch Therapeutics Group, Inc.
Industry: Medical - Drugs
With PRISM4 Discontinued, an Inflection Point in Business Strategy; Reiterate Buy With Adjusted PT of $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Finch Therapeutics Group, Inc.
Industry: Medical - Drugs
Company: Finch Therapeutics Group, Inc.
Industry: Medical - Drugs
CP101 PRISM4 Trial on Track to Continue Recruitment in 2H22; Reiterate Buy and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Finch Therapeutics Group, Inc.
Industry: Medical - Drugs
Restoring the Microbiome for Improved Disease Outcomes; Initiate at Buy and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
|